This inventor holds 1 USPTO granted patent and 4 published patent applications and 1 EPO patent. Top assignee: Principia Biopharma Inc.. Active years: 2017.
Company Filing History:
Years Active: 2017
Title: Martin Babler: Innovator in Dry Eye Treatment
Introduction
Martin Babler is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of ophthalmology, particularly in the treatment of dry eye. His innovative approach focuses on the inhibition of Bruton's tyrosine kinase (BTK) as a method for alleviating this common condition.
Latest Patents
Martin Babler holds a patent for a method of treating dry eye through the use of BTK inhibitors. This patent outlines pharmaceutical formulations that incorporate these inhibitors and details the processes for preparing such compounds. His work in this area has the potential to improve the quality of life for many individuals suffering from dry eye.
Career Highlights
Throughout his career, Martin has worked with several prominent companies, including Principia Biopharma Inc. and Hallux Inc. His experience in these organizations has allowed him to develop and refine his innovative ideas in the pharmaceutical industry.
Collaborations
Martin has collaborated with various professionals in his field, including Mary E. Gerritsen. These partnerships have contributed to the advancement of his research and the successful development of his patented treatments.
Conclusion
Martin Babler is a dedicated inventor whose work in the treatment of dry eye showcases his commitment to innovation in healthcare. His contributions are paving the way for new therapeutic options in ophthalmology.